|
|
Biotech
|
|
||
Snips & notes$MLNT downgraded to Hold from Speculative Buy at WBB Securities. PT $8 $GNCA prices offering. 10.5M shares at $3.50/share $ZYME prices $175M offering. @ $18 $CYRX Prices Offering. 3.75M Shares at $17/Share
HCW $AUPH Confident Current Board Defeats Proxy Challenge; Affirm Buy,continue to favor existing highly-experienced&accomplished Board, includingnew CEO,not only to successfully commercialize voclosporin full potential,but also continue to seek avenues to maximize value creation $VKTX believe VKTX (OP) will submit its IND package by end of summer that will lead to a Phase 2b study of VK2809 in NASH patients starting in 2H19. With current short interest being ~40% of float,expect a Phase 2b study initiation to drive shares higher through end of the year. LR $DCPH Bottom Line: believe that the Phase 3 INVICTUS trial in 4L + GIST is likely to be successful (we assign a 95% probability) given the placebo comparator, but that high expectations suggest a slight negative skew into the dataset for DCPH shares. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
27601 | Re: Snips & notes | minxmrphd | 6 | 6/20/2019 7:33:34 AM |